162252-92-8

Basic information

• Product Name: 6-(TRIFLUOROMETHOXY)-1H-INDOLE-2,3-DIONE
• Synonyms: 6-TRIFLUOROMETHOXYISATIN;6-(TRIFLUOROMETHOXY)-1H-INDOLE-2,3-DIONE;6-(trifluoromethoxy)indoline-2,3-dione;6-(trifluoroMethoxy)-2,3-dihydro-1H-indole-2,3-dione
• CAS NO: 162252-92-8
• Molecular Formula: C9H4F3NO3
• Molecular Weight: 231.13
• Mol File: 162252-92-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.562 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 8.69±0.20(Predicted)
• CAS DataBase Reference: 6-(TRIFLUOROMETHOXY)-1H-INDOLE-2,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(TRIFLUOROMETHOXY)-1H-INDOLE-2,3-DIONE(162252-92-8)
• EPA Substance Registry System: 6-(TRIFLUOROMETHOXY)-1H-INDOLE-2,3-DIONE(162252-92-8)

Safety Data

• Hazardous Substances Data: 162252-92-8(Hazardous Substances Data)

Usage

General Description

6-(Trifluoromethoxy)-1H-indole-2,3-dione, also known as CF3OC2H2(C(=O))2C8H5N with the CAS number 209714-62-0, is a specialized chemical compound that falls under the class of indolequiones, which are heterocyclic compounds characterized by an indole substituted by a quinone at two positions. The chemical compound exhibits a molecular formula of C11H5F3NO4 and a precise overall mass of 293.023437. There is currently limited information about the compound’s physical property, and the specific applications of this compound are not detailed widely in chemical literature, indicating that it may primarily be used for research purposes or specialized industrial applications.

Upstream product

• 461-82-5 4-(trifluoromethoxy)aniline 
• 1956-85-0 N-(3-(trifluoromethoxy)phenyl)acetamide 

Relevant articles and documents

Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF. Here, we report novel indolinone-based multikinase inhibitors that target angiogenesis and fibrosis pathways and may serve as potential therapeutics for IPF. KBP-7018 is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). The pharmacokinetics (PK) properties of KBP-7018 were favorable in mice, rats, and dogs. In a bleomycin (BLM)-induced mouse pulmonary fibrosis model, 10, 30, and 100 mg/kg daily doses (q.d.) of KBP-7018 improved the 28-day survival rate in a dose-dependent manner. The improved efficacy of KBP-7018 compared to nintedanib provided a certain level of chemical validation for the involvement of PDGFR, c-KIT, and RET in IPF. Thus, KBP-7018 represents a novel multikinase inhibitor with differentiated activity, highly enhanced selectivity, and acceptable PK profiles that will enter phase I clinical trials.

Rigid Analogs of Camptothecin as DNA Topoisomerase I Inhibitors

Substituted 8-ethyl-2-(2-oxo-1,2-dihydroindol-3-ylidene)-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-azacyclopentanaphthalene-1,4,7-triones were synthesized and evaluated as topoisomerase I inhibitors in an in vitro cleavable complex assay.The activity of these compounds may be attributed to their rigid, planar geometry, and an attempt was made to correlate the SAR in this series to known attributes of camptothecin.